TORONTO, Feb. 4, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, along with members of the Khiron management team, will host a live webcast on Wednesday, February 17 at 11:00am ET to discuss recent results and management's outlook for 2021.
Management will also be hosting a 1x1 Virtual Roadshow with Harbor Access February 9-10, 2021 and participating in the Benzinga Virtual Cannabis Capital Conference being held February 25-26, 2021. In addition, Mr. Torres will be participating in the Benzinga Cannabis Hour on Thursday, February 11, 2021 as a panelist discussing the international cannabis landscape.
In 2020, achieves 50% compound monthly growth rate (CMGR) in medical cannabis prescriptions (April to December), reaching 7,500 paid prescriptions as of January 31, 2021
Colombian government extends medical health insurance coverage to THC and CBD medical cannabis products, resulting in strong month-over-month growth in December 2020 and January 2021
On December 9th, Khiron opens new small-format clinic in Medellin, Colombia's 2nd largest city, as part of the Company's plan to extend its medical cannabis clinics across Colombia and Latin America.
Company appoints former Colombia Minister of Finance Juan Carlos Echeverry as an independent member of its Board of Directors
Khiron declared a National Strategic Project by the Government of Colombia, which simplifies and accelerates administration processes for the Company's strategic initiatives
Khiron is the first cannabis company in Colombia to ship THC products internationally
About Khiron Life Sciences Corp. Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Colombia, Peru and the UK, and is positioned to commence sales of medical cannabis in Germany and Brazil in early 2021.
Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with KuidaTM now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.